48
Participants
Start Date
September 30, 2024
Primary Completion Date
April 30, 2025
Study Completion Date
September 30, 2025
Sm-p80 + GLA-SE Vaccine
30 μg Sm-p80 + 5 μg GLA-SE
Placebo
0.9% Sterile Normal Saline
Schistosoma mansoni infection
20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain
Texas Tech University Health Sciences Center
OTHER
MRC/UVRI and LSHTM Uganda Research Unit
OTHER
Leiden University Medical Center
OTHER